Published in Hospital Business Week, May 25th, 2008
"In recent clinical trials, sunitinib has been associated with good response rates in patients with mRCC. The aim of this study was to analyze the cost-effectiveness of sunitinib as second-line therapy for cytokine-refractory mRCC compared with current routine clinical practice in Finland (ie, best supportive care [BSC], including palliative biochemotherapy). A probabilistic decision-analytic model was developed to...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hospital Business Week